|
|
| Research article summary (published 13 Nov 2009): |
Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
Full Abstract
Clear cell carcinoma (CCC) of the ovary is known to be highly resistant to platinum-based chemotherapy. The purpose of our study was to identify a candidate protein that is associated with chemoresistance of CCC and to investigate the specific mechanism of chemoresistance conferred by the identified protein. Enhanced expression of Annexin A4 (Anx A4) was identified in ovarian CCC cells using 2-D differential gel electrophoresis (2D-DIGE) and mass spectrometry. Anx A4 levels were elevated in CCC cells compared with non-CCC cells as determined by real-time RT-PCR and Western blot analysis. Immunohistochemical analysis of Anx A4 was performed in 126 epithelial ovarian cancer tissue samples and demonstrated significantly elevated levels of Anx A4 protein levels in ovarian CCC tumors compared with ovarian serous and endometrioid tumors (p < 0.01). Anx A4-transfected ovarian non-CCC cells were more resistant to carboplatin (IC50 = 42 microM) compared with control cells (IC50 = 23 microM) as determined by modified MTT assay. Intracellular platinum levels were significantly lower in Anx A4-transfected cells compared with control cells after carboplatin treatment (p = 0.0020) and after an additional 360 min of carboplatin-free incubation (p = 0.0004), as measured by atomic absorption spectrophotometry. Expression of Anx A4 is elevated in ovarian CCC tumors and is associated with chemoresistance in cultured ovarian cancer cells. These results demonstrate that Anx A4 confers chemoresistance in ovarian cancer cells in part by enhancing drug efflux. Thus, Anx A4 may represent a novel therapeutic target of chemoresistance in patients with ovarian CCC.
Author information
Author/s: Kim, Ayako (A); Enomoto, Takayuki (T); Serada, Satoshi (S); Ueda, Yutaka (Y); Takahashi, Tsuyoshi (T); Ripley, Barry (B); Miyatake, Takashi (T); Fujita, Masami (M); Lee, Chun Man (CM); Morimoto, Koji (K); Fujimoto, Minoru (M); Kimura, Tadashi (T); Naka, Tetsuji (T);
Affiliation: Department of Obstetrics and Gynaecology, Osaka University Graduate School of Medicine, Osaka, Japan.
Journal and publication information
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal: International journal of cancer. Journal international du cancer (Int J Cancer), published in United States. (Language: eng)
Reference: 2009-Nov; vol 125 (issue 10) : pp 2316-22
Dates: Created 2009/09/28; Completed 2009/11/05;
PMID: 19598262, status: MEDLINE (last retrieval date: 11/5/2009, IMS Date: )
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
Related articles
These are the highest related articles currently in the database:
- Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
30 Mar 2008 - Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
13 Jan 2003 - Morphological and phenotypic characterization of a new established ovarian carcinoma cell line (OvBH-1).
30 Aug 2000 - A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study.
30 Oct 2001 - Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma.
30 May 2005 - Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
11 Dec 2007 - Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
30 Mar 2008 - Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
30 May 2004 - Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
30 May 2000 - Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
13 Jan 2003
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a large map of 100+ related articles.